The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. Keeping that in mind, here is one stock where the poor sentiment is creating a buying opportunity and two facing legitimate challenges.
Two Stocks to Sell:
Belden (BDC)
One-Month Return: -21%
With its enamel-coated copper wire used in WWI for the Allied forces, Belden (NYSE: BDC) designs, manufactures, and sells electronic components to various industries.
Why Are We Hesitant About BDC?
- Eroding returns on capital suggest its historical profit centers are aging
Belden is trading at $106.13 per share, or 12.7x forward P/E. If you’re considering BDC for your portfolio, see our FREE research report to learn more.
PennyMac Financial Services (PFSI)
One-Month Return: -6%
Founded during the 2008 financial crisis to help address the mortgage market meltdown, PennyMac Financial Services (NYSE: PFSI) is a specialty financial services company that originates, services, and manages investments related to residential mortgage loans in the United States.
Why Is PFSI Not Exciting?
- Sales tumbled by 12.1% annually over the last five years, showing market trends are working against its favor during this cycle
- 4% annual net interest income growth over the last five years was slower than its banking peers
- Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable
PennyMac Financial Services’s stock price of $85.90 implies a valuation ratio of 1x forward P/B. Dive into our free research report to see why there are better opportunities than PFSI.
One Stock to Buy:
Insulet (PODD)
One-Month Return: -18.4%
Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ: PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.
Why Are We Bullish on PODD?
- Steady constant currency growth over the past two years shows the company can pursue its global ambitions, even in uncertain economic times
- Free cash flow margin jumped by 25.8 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Returns on capital are climbing as management makes more lucrative bets
At $154.70 per share, Insulet trades at 23.5x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
